| Literature DB >> 34290889 |
Indraneel Banerjee1, Indrajit Banerjee2, Shantimoy Banerjee3.
Abstract
Entities:
Year: 2021 PMID: 34290889 PMCID: PMC8266403 DOI: 10.3126/nje.v11i2.38133
Source DB: PubMed Journal: Nepal J Epidemiol
Simplified summary of the triage protocol to be followed in the management of Urological cancers during COVID-19
| Site of Cancer | Cancer stage | Management |
|---|---|---|
| cT1a | Postpone Sx for 6 months | |
| ≥cT1b | Postpone Sx for 3 months | |
| Any T, Hematuria/ | Immediate Sx | |
| Metastatic RCC IMDC Good and Intermediate risk | TTX, CN after 3-6 month | |
| Metastatic RCC IMDC poor risk | TTX | |
| Low risk | Postpone Sx for 3 months | |
| Intermediate risk | Prefer Sx | |
| High risk | Sx | |
| Any tumor with hematuria | Sx | |
| cT2N0 | Trimodal therapy/Sx | |
| ≥cT/ any N+ | Sx within 3 months | |
| pT3/T4, p N1-N3 | Defer adjuvant CT after Sx, Immuno preferred | |
| Metastatic bladder cancer | Defer CT, Immuno preferred | |
| Metastatic bladder cancer with hematuria | Hemostatic RT/Endoscopic fulguration | |
| Low risk | AS/Defer treatment for 6 months | |
| Intermediate risk | Defer treatment for 3-6 months | |
| High risk | Neoadjuvant ADT for 3-6 months followed by Sx/RT | |
| Metastatic | LHRH agonist preferred | |
| CRPC | Abiraterone/Enzalutamide preferred. Avoid Docetaxel CT. | |
| cTis, cTa, cT1 | Postpone Sx for 3 months | |
| cT2/cT3 | Sx | |
| cT4 | Sx + adjuvant CT | |
| Low risk | Surveillance | |
| Intermediate risk | Surveillance | |
| High risk | Sx postponed for 3 months | |
| Positive mobile nodes | Sx | |
| Positive fixed nodes/>4cm | Neoadjuvant CT followed by Sx | |
| Metastatic disease | Palliative CT | |
| CS I Low risk | Surveillance | |
| CS I High risk | Surveillance/CT | |
| CS II A, IIB | CT/RT | |
| CS IIC, III | CT | |
| CS I A | Surveillance | |
| CS IB | Surveillance | |
| CS IS | CT | |
| CS IIA, IIB | CT | |
| CS II C, III | ||
| Good risk | CT | |
| Intermediate risk | CT | |
| High risk | CT |
Sx: Surgery, TTx: Targeted therapy, CN: Cytoreductive nephrectomy, NMIBC: Non muscle invasive bladder cancer, MIBC: Muscle invasive balader cancer, CT: Chemotherapy, RT: Radiotherapy, AS: Active surveillance,
Steps enumerating precautions to be taken during Robotic surgery in Urological Cancer patients to prevent contamination from COVID-19 infection
| Workflow | Action to be taken |
|---|---|
Postpone all non-emergency/non urgent procedures (vide Avoid surgery on COVID-19 positive patients (if applicable) | |
Prefer telehealth consultation Screening for Covid-19 symptoms, travel history and exposure history. Covid-19 RT PCR/HRCT chest in all patients posted for surgery. Counselling for possible risk of contracting Covid-19 infection during hospital admission. | |
>20 air changes/hour HEPA filters for air filtration. Cleaning of Robotic console head support between each case. Entry and exit in OR to be restricted Use PPE Use Video laryngoscopy for intubation HEPA filter attached to the endotracheal tube before intubation Minimize risk of aerosol formation Only the anesthesia team members should be present during intubation and extubating | |
All cases are to be done by experts Surgeon console can be kept outside OR Only single bedside assistant. Bedside assistant should use PPE. Keep pneumoperitoneum at minimum (5 mmHg) and use Air Seal device. Minimize instrument entry and exit and minimize air leak Avoid ultrasonic sealing devices and keep the diathermy setting at minimum Use Air Seal to suck all the CO2 at the end of the procedure. If Air Seal device is not available use a smoke evacuator connected to a HEPA filter/underwater seal using sodium hypochlorite solution. |
HRCT: High resolution CT, HEPA: High efficiency particulate air, OR: Operating room